Central nervous system event in patients with diffuse large B-cell lymphoma in the rituximab era

Cancer Science

Volumn 103, Issue 2, 2012, Pages 245-251

  Tomita, Naoto ^a,b   Yokoyama, Masahiro ^a,c,d   Yamamoto, Wataru ^e   Watanabe, Reina ^b   Shimazu, Yutaka ^f   Masaki, Yasufumi ^g   Tsunoda, Saburo ^h   Hashimoto, Chizuko ^e   Murayama, Kayoko ⁱ   Yano, Takahiro ^j   Okamoto, Rumiko ^k   Kikuchi, Ako ^l   Tamura, Kazuo ^m   Sato, Kazuya ⁿ   Sunami, Kazutaka ^o   Shibayama, Hirohiko ^p   Takimoto, Rishu ^q   Ohshima, Rika ^r   Hatta, Yoshihiro ^s   Moriuchi, Yukiyoshi ^t   Kinoshita, Tomohiro ^u   Yamamoto, Masahide ^v   Numata, Ayumi ^w   Ishigatsubo, Yoshiaki ^b   Takeuchi, Kengo ^a,d,x   more..

^a Bay area Lymphoma Information Network   (Japan)

^b YOKOHAMA CITY UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^c CANCER INSTITUTE HOSPITAL   (Japan)

^d Ganken Ariake Lymphoma Study Group   (Japan)

^e KANAGAWA CANCER CENTER   (Japan)

^f KYOTO UNIVERSITY   (Japan)

^g KANAZAWA MEDICAL UNIVERSITY   (Japan)

^h TOCHIGI CANCER CENTER   (Japan)

ⁱ Gunma Cancer Center   (Japan)

^j NATIONAL HOSPITAL ORGANIZATION TOKYO MEDICAL CENTER   (Japan)

^k TOKYO METROPOLITAN KOMAGOME HOSPITAL   (Japan)

^l TOKAI UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^m FUKUOKA UNIVERSITY   (Japan)

ⁿ JICHI MEDICAL UNIVERSITY   (Japan)

^o NATIONAL HOSPITAL ORGANIZATION   (Japan)

^p OSAKA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^q SAPPORO MEDICAL UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^r YOKOHAMA CITY UNIVERSITY MEDICAL CENTER   (Japan)

^s NIHON UNIVERSITY SCHOOL OF MEDICINE   (Japan)

^t Sasebo Shiritsu Sogo Hospital   (Japan)

^u NAGOYA UNIVERSITY GRADUATE SCHOOL OF MEDICINE   (Japan)

^v TOKYO MEDICAL AND DENTAL UNIVERSITY   (Japan)

^w Fujisawa City Hospital   (Japan)

^x CANCER CHEMOTHERAPY CENTER   (Japan)

more..

Author keywords

[No Author keywords available]

Indexed keywords

CD20 ANTIGEN; CYCLOPHOSPHAMIDE; DOXORUBICIN; PREDNISOLONE; RITUXIMAB; VINCRISTINE;

ADOLESCENT; ADRENAL GLAND; ADULT; AGED; ARTICLE; BONE; BREAST; CANCER CHEMOTHERAPY; CANCER IMMUNOTHERAPY; CANCER SURVIVAL; CENTRAL NERVOUS SYSTEM DISEASE; FEMALE; HUMAN; JAPANESE; LARGE CELL LYMPHOMA; MAJOR CLINICAL STUDY; MALE; OVERALL SURVIVAL; PRIORITY JOURNAL; PROBABILITY; PROPHYLAXIS; RETROSPECTIVE STUDY; RISK FACTOR; SURVIVAL RATE;

ADOLESCENT; ADRENAL GLANDS; ADULT; AGED; AGED, 80 AND OVER; ANTIBODIES, MONOCLONAL, MURINE-DERIVED; ANTINEOPLASTIC COMBINED CHEMOTHERAPY PROTOCOLS; BONE AND BONES; BREAST; CENTRAL NERVOUS SYSTEM; CENTRAL NERVOUS SYSTEM NEOPLASMS; CYCLOPHOSPHAMIDE; DOXORUBICIN; FEMALE; HUMANS; JAPAN; LYMPHOMA, LARGE B-CELL, DIFFUSE; MALE; MIDDLE AGED; PREDNISOLONE; RETROSPECTIVE STUDIES; RISK FACTORS; TESTIS; VINCRISTINE; YOUNG ADULT;

EID: 84856418047     PISSN: 13479032     EISSN: 13497006     Source Type: Journal    
DOI: 10.1111/j.1349-7006.2011.02139.x     Document Type: Article

References (30)

1. Recht L, Straus DJ, Cirrincione C et al. Central nervous system metastases from non-Hodgkin's lymphoma: treatment and prophylaxis. Am J Med 1988; 84: 425-35.
2. Bashir RM, Bierman PJ, Vose JM et al. Central nervous system involvement in patients with diffuse aggressive non-Hodgkin's lymphoma. Am J Clin Oncol 1991; 14: 478-82.
3. Zinzani PL, Magagnoli M, Frezza G et al. Isolated central nervous system relapse in aggressive non-Hodgkin's lymphoma: the Bologna experience. Leuk Lymphoma 1999; 32: 571-6.
4. Tomita N, Kodama F, Sakai R et al. Predictive factors for central nervous system involvement in non-Hodgkin's lymphoma: significance of very high serum LDH concentrations. Leuk Lymphoma 2000; 38: 335-43.
5. Haioun C, Besson C, Lepage E et al. Incidence and risk factors of central nervous system relapse in histologically aggressive non-Hodgkin's lymphoma uniformly treated and receiving intrathecal central nervous system prophylaxis: a GELA study on 974 patients. Groupe d'Etudes des Lymphomes de l'Adulte. Ann Oncol 2000; 11: 685-90.
6. Jahnke K, Thiel E, Martus P et al. Retrospective study of prognostic factors in non-Hodgkin lymphoma secondarily involving the central nervous system. Ann Hematol 2006; 85: 45-50.
7. Perez-Soler R, Smith TL, Cabanillas F. Central nervous system prophylaxis with combined intravenous and intrathecal methotrexate in diffuse lymphoma of aggressive histologic type. Cancer 1986; 57: 971-7.
8. Bollen EL, Brouwer RE, Hamers S et al. Central nervous system relapse in non-Hodgkin lymphoma. A single-center study of 532 patients. Arch Neurol 1997; 54: 854-9.
9. Chua SL, Seymour JF, Streater J et al. Intrathecal chemotherapy alone is inadequate central nervous system prophylaxis in patients with intermediate-grade non-Hodgkin's lymphoma. Leuk Lymphoma 2002; 43: 1783-8.
10. Tomita N, Kodama F, Kanamori H et al. Prophylactic intrathecal methotrexate and hydrocortisone reduces central nervous system recurrence and improves survival in aggressive non-Hodgkin lymphoma. Cancer 2002; 95: 576-80.
11. Tilly H, Lepage E, Coiffier B et al. Intensive conventional chemotherapy (ACVBP regimen) compared with standard CHOP for poor-prognosis aggressive non-Hodgkin lymphoma. Blood 2003; 102: 4284-9.
12. Arkenau HT, Chong G, Cunningham D et al. The role of intrathecal chemotherapy prophylaxis in patients with diffuse large B-cell lymphoma. Ann Oncol 2007; 18: 541-5.
13. Cheung CW, Burton C, Smith P et al. Central nervous system chemoprophylaxis in non-Hodgkin lymphoma: current practice in the UK. Br J Haematol 2005; 131: 193-200.
14. Hill QA, Owen RG. CNS prophylaxis in lymphoma: who to target and what therapy to use. Blood Rev 2006; 20: 319-32.
15. Tomita N, Kodama F, Kanamori H et al. Secondary central nervous system lymphoma. Int J Hematol 2006; 84: 128-35.
16. van Besien K, Gisselbrecht C, Pfreundschuh M, Zucca E. Secondary lymphomas of the central nervous system: risk, prophylaxis and treatment. Leuk Lymphoma 2008; 49: 52-8.
17. Coiffier B, Lepage E, Briere J et al. CHOP chemotherapy plus rituximab compared with CHOP alone in elderly patients with diffuse large-B-cell lymphoma. N Engl J Med 2002; 346: 235-42.
18. Sehn LH, Berry B, Chhanabhai M et al. The revised International Prognostic Index (R-IPI) is a better predictor of outcome than the standard IPI for patients with diffuse large B-cell lymphoma treated with R-CHOP. Blood 2007; 109: 1857-61.
19. Hollender A, Kvaloy S, Nome O et al. Central nervous system involvement following diagnosis of non-Hodgkin's lymphoma: a risk model. Ann Oncol 2002; 13: 1099-107.
20. Boehme V, Zeynalova S, Kloess M et al. Incidence and risk factors of central nervous system recurrence in Aggressive lymphoma-a survey of 1693 patients treated in protocols of the German High-Grade Non-Hodgkin's Lymphoma Study Group (DSHNHL). Ann Oncol 2007; 18: 149-57.
21. Boehme V, Schmitz N, Zeynalova S et al. CNS events in elderly patients with aggressive lymphoma treated with modern chemotherapy (CHOP-14) with or without rituximab: an analysis of patients treated in the RICOVER-60 trial of the German High-Grade Non-Hodgkin Lymphoma Study Group (DSHNHL). Blood 2009; 113: 3896-902.
22. Kikuchi A, Kawada H, Iwaki Y et al. Measurement of rituximab concentration in the cerebrospinal fluid in CNS lymphoma. Rinsho Ketsueki 2004; 45: 1255-7 (Japanese).
23. Shahab N, Doll DC. Testicular lymphoma. Semin Oncol 1999; 26: 259-69.
24. Zucca E, Conconi A, Mughal TI et al. Patterns of outcome and prognostic factors in primary large-cell lymphoma of the testis in a survey by the International Extranodal Lymphoma Study Group. J Clin Oncol 2003; 21: 20-7.
25. Feugier P, Virion JM, Tilly H et al. Incidence and risk factors for central nervous system occurrence in elderly patients with diffuse large-B-cell lymphoma: influence of rituximab. Ann Oncol 2004; 15: 129-33.
26. Shimazu Y, Notohara K, Ueda Y. Diffuse large B-cell lymphoma with central nervous system relapse: prognosis and risk factors according to retrospective analysis from a single-center experience. Int J Hematol 2009; 89: 577-83.
27. Villa D, Connors JM, Shenkier TN et al. Incidence and risk factors for central nervous system relapse in patients with diffuse large B-cell lymphoma: the impact of the addition of rituximab to CHOP chemotherapy. Ann Oncol 2010; 21: 1046-52.
28. Yamamoto W, Tomita N, Watanabe R et al. Central nervous system involvement in diffuse large B-cell lymphoma. Eur J Haematol 2010; 85: 6-10.
29. Non Hodgkin's Lymphoma Clinical Practice Guidelines in Oncology. National Comprehensive Cancer Network. [Cited 10 July 2011.] Available from URL:
30. Avilés A, Delgado S, Nambo MJ et al. Primary breast lymphoma: results of a controlled clinical trial. Oncology 2005; 69: 256-60.